AsiaPharm re-rate by Phillip securities Research.

AsiaPharm Group Ltd recently acquisition of CMNa and Solid Success Group could be possible to become one of the China's Top ten players in the cancer drug industry. The forecasted projection growth for the coming future need to do an adjustment in it's value, because those increased asset are able to get more revenue and increase of business market share (increase the strength in market position in China). This is to be believe there is a significant boost in AsiaPharm's revenue and the profit for the coming future. market analyst forecasted is about double-digit growth for the coming future earning.

The recent collaboration with KKC Corporation Co. Ltd (KKC)could help in conducting the cancer drug clinical trials process in Korea by effective cost saving and that will also help to obtain the necessary approvals to distribute cancer drug in Korea market. This is an incentive to Asiapharm in Korea market.

The company's management will continues to look for more value acquisition in the coming future and this is to done by issues new share placements.

On the other hand most of the Fund manager predicted China domestic market will growth as the certain percentage of the China population getting urbanize where demand is created and the living standard is improve. I believe that AsiaPharm are able to play a important role in China's market in the coming future.

AsiaPharm fair value is S$0.92 - Phillip securities Research